The current stock price of SILO is 0.3451 USD. In the past month the price increased by 1.5%. In the past year, price decreased by -78.57%.
ChartMill assigns a technical rating of 1 / 10 to SILO. When comparing the yearly performance of all stocks, SILO is a bad performer in the overall market: 96.06% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to SILO. SILO has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months SILO reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 21.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.51% | ||
| ROE | -101.36% | ||
| Debt/Equity | 0 |
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
SILO PHARMA INC
677 N Washington Blvd
Sarasota FLORIDA US
Employees: 3
Phone: 17184009031
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
The current stock price of SILO is 0.3451 USD. The price increased by 4.93% in the last trading session.
SILO does not pay a dividend.
SILO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
The Revenue of SILO PHARMA INC (SILO) is expected to decline by 0% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
SILO PHARMA INC (SILO) has a market capitalization of 4.60M USD. This makes SILO a Nano Cap stock.
You can find the ownership structure of SILO PHARMA INC (SILO) on the Ownership tab.